Axogen reported a slight decrease in revenue for Q4 2021 compared to the previous year, but showed improvements in gross margin. The company is focused on expanding its core accounts and is looking forward to the results of its RECON study.
Net revenue was $31.5 million, a 3% decrease compared to Q4 2020.
Gross margin was 82.8% compared to 83.2% in Q4 2020.
Adjusted net loss was $3.3 million, or $0.08 per share, consistent with Q4 2020.
Cash, cash equivalents, and investments totaled $90.3 million.
Management expects 2022 revenue will be in the range of $135.0 million to $142.0 million. This represents approximately 10% to 15% growth over 2021 revenue excluding the impact of $4.1 million of Avive revenue in 2021. Full-year 2022 gross margin is expected to be above 80%.